

EFSPI Statistical Leaders Meeting

June 20, 2012 Weesp, The Netherlands



Welcome

- 3rd European Statistical Leaders Meeting
- Thank you to organising team
 - Stefan
 - Egbert
 - Uli
 - lan
 - Sara
 - Kit
- Thank you Abbott
 - for Hosting the Meeting
 - Sponsoring the Dinner



Agenda

Time	Topic	Presentor / Facilitator
9:00-9:20	•EFSPI President Welcome address •Organisers welcome	Francois Aubin Stefan Driessen
9:20-10:30	•Risk Benefit (web-ex)	Ian Hirsch / Sara Hughes
10:30-11:00	Break	
11:00-12:00	•Adaptive statisticians & the challenges beyond Clinical Trials	Kit Roes / Egbert Biesheuvel
12:00-13:00	Lunch break	
13:00-13:20	•SIG Update	Stefan Driessen
13:25-13:45	•Career Path	Hans Ulrich Burger
13:45-15:45	•Strategic Do's and Don'ts for the statistical community in EU Pharma	All
16:15	•Meeting summary and actions	Stefan Driessen
16:30	Meeting adjourn	3



What is EFSPI?

- EFSPI = European Federation of Statisticians in the Pharmaceutical Industry
- Founded in 1992
- EFSPI is an "umbrella", non-profit making organisation
- A federation of National European Groups
- Now have 10 national groups
- No individual members
- Our national organisations collectively represent 2800 members



EFSPI - Our members





EFSPI Objectives

- To promote professional standards of statistics and the standing of the statistical profession in the pharmaceutical industry
- To offer a collective expert input on statistical matters to national and international authorities and organisations
- To exchange information on and harmonise attitudes to the practise of statistics in the European Pharma Industry and within member groups



Key Objectives for 2012

- Build a stronger European platform for statistical interaction
 - Statistical Leaders Meeting
- Use Statistical Leaders Meeting to develop our strategy for the future
- Deliver three quality European Statistical Meetings
 - Benefit-Risk Assessment Methodology 7 June
 - Modelling and Simulation 13 September
 - Subgroup Analyses 30 November
- Provide Cross-industry review of key regulatory documents (Regulatory Committee)
- Make more effective use of the EFSPI website



What we can achieve?

Successfully supported PSI in lobbying EU Regulators to increase number of statisticians employed by the EU Regulatory Agencies

Heads of Agencies listened and then commissioned a Strategy Paper to investigate the matter further

European regulatory agencies should employ full time

Statisticians Sara Hughes, chair of PSI (professional UK body of statisticians in the pharmaceutical industry) and director

of statistics, GlaxoSmithKline chair@psiweb.org Nigel Howitt, EFSPI president (European Federation of Statisticians in the Pharmaceutical Industry) and director of analysis and reporting, PRA International;

Kit Roes, EFSPI vice president and vice president, Global Clinical Information. Organon Schering-Plough:

BMI | 2 FEBRUARY 2008 | VOLUME 336

VIEWPOINT

Pharmaceutical Statistics

Received 1 December 2009

Accepted 19 December 2009

Published online 8 February 2010 in Online Library

(wileyonlinelibrary.com) DOI: 10.1002/pst.416

Statistical resource needs to be increased in the European regulatory agencies

Oliver N. Keene, Sara H. Hughes, Nigel Howitt, on behalf of the PSI and **EFSPI Boards of Directors**

The following viewpoint from PSI and EFSPI regarding the current level of statistical resource in the European regulatory agencies was first presented as a position paper to a meeting of the EU Heads of Agencies in July 2009, and was endorsed by EFPIA. Copyright © 2010 John Wiley & Sons, Ltd.

PHARMACEUTICAL STATISTICS

Pharmaceut. Statist. (2009)

Published online in Wiley InterScience

(www.interscience.wiley.com) DOI: 10.1002/pst.367

Statisticians in European regulatory agencies

Eva Skovlund^{1,2,*,†}

Norwegian Medicines Agency, Oslo, Norway

²School of Pharmacy, University of Oslo, Oslo, Norway



What we can achieve?

Main Paper

Pharmaceutical Statistics

(wileyonlinelibrary.com) DOI: 10.1002/pst.508

Published online in Wiley Online Library

The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians

Bernhard Huitfeldt, a* and Jürgen Hummel, on behalf of European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)

The European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) engages more than 2000 statisticians through its ten national organizations. Amongst other things, EFSPI is involved in reviewing regulatory guidelines under development, including the draft FDA guideline on non-inferiority clinical trials. This review resulted in several critical comments relating to as follows: (i) the lack of one single standard for proving efficacy of new drugs implied by the guideline; (ii) the problems with the suggested 'fraction of effect to be preserved'; (iii) the formulation of the primary hypothesis in a non-inferiority trial aiming at indirectly demonstrating a new drug is superior to placebo; and (iv) the preference in the guideline for the fixed-margin method over the synthesis method in the analysis. The presumed implications of this guideline, if implemented as is, are (i) increased confusion of how efficacy could be demonstrated when placebo control is not available, (ii) more complicated communication between pharmaceutical industry and FDA because of the apparent disagreements on fundamental statistical matters, and (iii) illogical consequences in the approval process because of which order drugs are approved rather than how they fulfill the regulatory requirements. We believe that the area is not yet ready for such a prescriptive regulatory guidance and that further research and experience are required until the methodology can be finally agreed. A strategy needs to be developed by regulatory agencies together with drug industry and academia for a long term solution for this topic. Copyright © 2011 John Wiley & Sons, Ltd.

Keywords: FDA guideline; non-inferiority; synthesis method; fixed-margin method; EFSPI

September 2011



www.efspi.org






!!! 2013 !!!





2013 Year of Statistics





2013 Year of Statistics

EFSPI is participating

Participants

Professional societies

- o (Australia) Statistical Society of Australia
- o (Austria) Austrian Statistical Society
- o (Belgium) Belgian Statistical Society
- o (Botswana) Botswana Statistical Association
- (Brazil) <u>Brazilian Statistical Association</u>
- o (Canada) Southern Ontario Regional Association of the Statistical Society of Canada
- o (Canada) Statistical Society of Canada
- (Congo) <u>Association des Statisticiens du Congo (DRC)</u>, <u>ASTACO</u>
- (Croatia) <u>Teachers Association "Suradnici u ucenju"</u>
- (Czech Republic) <u>Czech Statistical Society</u>
- (Denmark) <u>Danish Society of Theoretical Statistics</u>
- (Estonia) <u>Estonian Statistical Society</u>
- o (Estonia) Statistics Estonia
- o (Ethiopia) Ethiopian Statistical Association
- o (Europe) European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)





Statistical Leaders Meeting

- Develop a forum for Statistical Leaders to
 - Network and share ideas
 - Shape and influence our environment
 - Education & Continuing Professional Development
 - Methodology Development & Identification of Best Practice
 - Regulatory and Industry policies
 - Effective working with differing resourcing models
 - Help to shape the strategy for EFSPI



Objectives 2012 meeting

- 1. To identify priorities for the strategic direction of EFSPI in
 - Evaluation of Risk Benefit
 - Challenges to statisticians beyond Clinical trials
 - SIGs
 - Career Path



Format

- First two topics will be presented followed by:
 - Facilitated discussion to identify 3 priority actions
 - Facilitators will summarise key actions at the end of each discussion
- The other two presentations will be updates from previous Statistical Leaders Meetings and also will contribute to 2nd objective



Objectives 2012 meeting

2. To define goals and a road map to help the individual EU pharmaceutical statistician to best influence their future, and thus ourselves, in order to secure and grow the statistical community in EU in the pharmaceutical/life sciences industry



Format


- Open Space workshop
 - 4 areas of interest to be identified
 - One facilitator per table
 - Per topic/area/item:
 - 3 Outcomes to describe on flip charts
 - Present back outcomes
 - Plenary session



Areas as pre-read

Specialist
Operational
Career
Manager

Coming from LUNCH BREAK



Technical
Training / Skill Set
Impact fullness
communication

Accreditation

Decreasing "supply" statisticians

Miscellaneous

Business Model